Provided by Tiger Trade Technology Pte. Ltd.

GlucoTrack, Inc.

2.55
-0.6800-21.05%
Post-market: 2.41-0.1400-5.49%19:59 EDT
Volume:744.25K
Turnover:2.12M
Market Cap:1.80M
PE:-0.02
High:3.06
Open:3.06
Low:2.26
Close:3.23
52wk High:212.10
52wk Low:2.26
Shares:705.25K
Float Shares:701.36K
Volume Ratio:15.80
T/O Rate:106.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-112.7747
EPS(LYR):-468.2383
ROE:-620.63%
ROA:-164.45%
PB:-1.03
PE(LYR):-0.01

Loading ...

Update – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-controlled Public Platform

THOMSON REUTERS
·
Jul 17

Press Release: Update

Dow Jones
·
Jul 17

Glucotrack - Lokahi Therapeutics Becomes Wholly Owned Subsidiary of Glucotrack - SEC Filing

THOMSON REUTERS
·
Jul 16

Glucotrack - Lokahi Shareholders to Receive 19.99% of Glucotrack Common Stock Outstanding as of Merger Date - SEC Filing

THOMSON REUTERS
·
Jul 16

Glucotrack - Enters Merger Agreement with Lokahi Therapeutics on July 14, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 16

Top Premarket Gainers

MT Newswires Live
·
Jul 15

GlucoTrack, Lokahi Therapeutics Complete Merger

MT Newswires Live
·
Jul 15

YSX Tech Stock Soars 14% After Hours: Here's Why

Benzinga Earnings
·
Jul 15

Glucotrack (GCTK) Stock Is Trending Overnight — Here’s Why it Spiked Over 69% in After-Hours Session

Benzinga_recent_news
·
Jul 15

Glucotrack Names Erik Emerson CEO, Paul Goode CTO in Lōkahi Deal

Reuters
·
Jul 15

Press Release: Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-controlled Public Platform

Dow Jones
·
Jul 15

GlucoTrack announces USPTO notice of allowance for patent application

TIPRANKS
·
Jul 08

Glucotrack Says USPTO Allows Patent Claims for Implantable Continuous Blood Glucose Monitoring Platform

Reuters
·
Jul 08

Glucotrack Announces Uspto Notice of Allowance for Patent Application Covering Its Implantable Cbgm Platform

THOMSON REUTERS
·
Jul 08

GlucoTrack announces 2026 annual shareholder meeting

Reuters
·
Jun 18

GlucoTrack IDE submission enters FDA review for implantable blood glucose monitor

Reuters
·
May 26

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions

GlobeNewswire
·
May 26

GlucoTrack faces Nasdaq delisting over minimum bid price deficiency

Reuters
·
May 16

GlucoTrack's Q1 net loss narrows

Reuters
·
May 15

GlucoTrack Q1 EPS $(2.65) Up From $(40.20) YoY

Benzinga Earnings
·
May 15